Rx Label "Highlights" Under FDA Rule Could Yield Inconsistencies - Merck
Executive Summary
Information included in the "Highlights" summary section of drug labeling under FDA's proposed rule would likely be inconsistent from product to product, Merck said in comments on FDA's proposed labeling rule.
You may also be interested in...
Physician Labeling Rule Could Save Up To $443 Mil. Over 10 Years – FDA
FDA's physician labeling rule will yield between $373 mil. and $443 mil. in net benefits over 10 years, according to the agency's cost-benefit analysis of the regulation
Physician Labeling Rule Could Save Up To $443 Mil. Over 10 Years – FDA
FDA's physician labeling rule will yield between $373 mil. and $443 mil. in net benefits over 10 years, according to the agency's cost-benefit analysis of the regulation
Labeling Format Differentiation Minimized By Rule Implementation Timeline
FDA's implementation timeline for the physician labeling rule may mean that advent of the new labeling format will have limited impact on currently available competing products